The PD-1/PD-Ligand pathways are major regulators of effector T cell responses in normal and pathologic conditions, including cancer, infectious and autoimmune disease, and have emerged as important targets for cancer immunotherapy (Sharma and Allison, 2015a, Sharma and Allison, 2015b). The gene discussed is PDCD1; the disease is cancer.